Illumina, Inc. $ILMN Shares Sold by Moloney Securities Asset Management LLC

Moloney Securities Asset Management LLC lowered its position in Illumina, Inc. (NASDAQ:ILMN) by 3.9% in the second quarter, HoldingsChannel reports. The firm owned 3,342 shares of the life sciences company’s stock after selling 134 shares during the period. Moloney Securities Asset Management LLC’s holdings in Illumina were worth $319,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Rise Advisors LLC grew its holdings in shares of Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 224 shares during the period. Cullen Frost Bankers Inc. purchased a new position in Illumina during the second quarter worth about $41,000. Golden State Wealth Management LLC boosted its stake in Illumina by 123.2% during the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock worth $42,000 after buying an additional 292 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in shares of Illumina by 2,936.8% in the first quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock valued at $46,000 after purchasing an additional 558 shares during the period. Finally, WPG Advisers LLC purchased a new position in shares of Illumina in the first quarter valued at approximately $58,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 0.1%

Shares of NASDAQ:ILMN opened at $100.11 on Friday. The firm’s 50 day moving average price is $98.17 and its 200 day moving average price is $91.65. The stock has a market cap of $15.39 billion, a price-to-earnings ratio of 12.67, a price-to-earnings-growth ratio of 2.47 and a beta of 1.40. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.17. The firm had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm’s revenue was down 4.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the subject of several recent research reports. Daiwa Capital Markets lowered shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price objective for the company. in a research note on Tuesday, August 12th. Evercore ISI lowered their price objective on shares of Illumina from $135.00 to $132.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Daiwa America lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 12th. Weiss Ratings reissued a “sell (d+)” rating on shares of Illumina in a research note on Saturday. Finally, Citigroup lowered shares of Illumina from a “hold” rating to a “strong sell” rating and lowered their price objective for the company from $85.00 to $80.00 in a research note on Wednesday, July 9th. Five analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Illumina has a consensus rating of “Hold” and a consensus target price of $115.25.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.